Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia

Trial Profile

Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buspirone/Zolmitriptan (Primary)
  • Indications Dyskinesias; Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Contera Pharma

Most Recent Events

  • 14 Oct 2024 Status changed from recruiting to discontinued.
  • 01 Oct 2023 This study has been completed in France, as per European Clinical Trials Database record
  • 29 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top